COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITING AGENT AND A NUCLEAR HORMONE RECEPTOR LIGAND FOR TREATING CARDIOVASCULAR CONDITIONS

摘要

A therapeutic combination, useful in a co-therapy method for improving cardiovascular performance and/or treating cardiovascular diseases, is provided comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand.